Search Results 121-130 of 8372 for TNF
Patient must receive anti-TNF treatment within 2 months following enrollment into the registry. Patient is currently receiving immunosuppressant therapy for ...
... Tumor Necrosis Factor (TNF) therapy. A Study to Evaluate the Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy Jacksonville, FL.
His research laboratory focuses on epigenetics, TNF-alpha and inflammatory signaling, and senescence in PKD, among other mechanisms. Funding. The Mayo Clinic ...
... tumor necrosis factor-alpha (TNF-α) antagonist for their underlying CD (does not require treatment failure for currently active draining fistula). France ...
... tumor necrosis factor (TNF) or anti-interleukin (IL)-6 agents are excluded * Participants still recovering from toxicity of prior anticancer therapy which ...
Tumor necrosis factor-alpha (TNF- alpha) inhibitors — TNF-alpha is an inflammatory substance produced by your body. TNF-alpha inhibitors block this substance.
Contraindications to the use of golimumab or infliximab or anti-tumor necrosis factor (TNF-alpha) therapy per local prescribing information. Participating ...
anti-Tumor necrosis factor(TNF) Monoclonal antibodies (mAb), or Belatacept, abatacept, Janus kinase inhibitors) 4. Transplant in which the kidney donor is ...
Inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or Tumor necrosis factor-alpha (TNF-α) antagonists.
For example, patients who are receiving combination therapy with anti-TNF ... Examining clinical and genetic factors that impact response to anti-TNF agents in ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.